|
[1]
|
Is sea buckthorn berry a sustainable intervention for the modulation of cardiometabolic risk factors? An updated, critical synthesis of randomized controlled trials with meta-analysis, trial sequential analysis, and GRADE certainty assessment
Trends in Food Science & Technology,
2026
DOI:10.1016/j.tifs.2025.105454
|
|
|
|
|
[2]
|
Sea buckthorn triterpenic acids alleviates metabolic dysfunction-associated steatotic liver disease via modulation of liver biochemistry, lipid metabolism and AMPK/Nrf2/NF-κB signaling pathway
Food Bioscience,
2025
DOI:10.1016/j.fbio.2025.106611
|
|
|
|
|
[3]
|
Sea buckthorn bioactive metabolites and their pharmacological potential in digestive diseases
Frontiers in Pharmacology,
2025
DOI:10.3389/fphar.2025.1637676
|
|
|
|
|
[4]
|
The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis
Cardiovascular & Hematological Disorders-Drug Targets,
2025
DOI:10.2174/011871529X360903250211101856
|
|
|
|
|
[5]
|
Exploring the effect and mechanism of Hippophae rhamnoides L. triterpenoid acids on improving NAFLD based on network pharmacology and experimental validation in vivo and in vitro
Journal of Ethnopharmacology,
2024
DOI:10.1016/j.jep.2024.118657
|
|
|
|
|
[6]
|
A Review on the Protecting Effects and Molecular Mechanisms of Berries Against a Silent Public Health Concern: Non-Alcoholic Fatty Liver Disease
Antioxidants,
2024
DOI:10.3390/antiox13111389
|
|
|
|
|
[7]
|
Effects of sea buckthorn (Hippophae rhamnoides L.) on factors related to metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trial
Phytotherapy Research,
2022
DOI:10.1002/ptr.7596
|
|
|
|
|
[8]
|
Phytochemistry and pharmacology of sea buckthorn (Elaeagnus rhamnoides; syn. Hippophae rhamnoides): progress from 2010 to 2021
Phytochemistry Reviews,
2022
DOI:10.1007/s11101-022-09832-1
|
|
|
|
|
[9]
|
Management of High Altitude Pathophysiology
2018
DOI:10.1016/B978-0-12-813999-8.00003-3
|
|
|
|
|
[10]
|
Effect of sea buckthorn (Hippophae rhamnoides L.) on blood lipid profiles: A systematic review and meta-analysis from 11 independent randomized controlled trials
Trends in Food Science & Technology,
2017
DOI:10.1016/j.tifs.2016.11.007
|
|
|
|
|
[11]
|
Ezetimibe alleviates non-alcoholic fatty liver disease through the miR-16 inhibiting mTOR/p70S6K1 pathway
RSC Adv.,
2017
DOI:10.1039/C7RA03949B
|
|
|
|